Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
InflaRx N.V. Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.	United States of America	IFRX
Inhibikase Therapeutics, Inc. Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.	United States of America	IKT
Inhibrx Biosciences, Inc. Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.	United States of America	INBX
InMed Pharmaceuticals Inc. Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.	United States of America	INM
Inmune Bio, Inc. Develops immunotherapies reprogramming innate immunity for cancer, Alzheimer's, and inflammation.	United States of America	INMB
Innate Pharma SA Developing first-in-class antibody immunotherapies for cancer via the innate immune system.	United States of America	IPHA
INOVIO PHARMACEUTICALS, INC. Develops DNA medicines delivered via smart devices for cancer, HPV, and infectious diseases.	United States of America	INO
Insight Molecular Diagnostics Inc. Develops molecular diagnostic tests for oncology and transplant monitoring for clinicians & researchers.	United States of America	IMDX
INSMED Inc Develops and commercializes innovative therapies for serious and rare diseases.	United States of America	INSM
Instil Bio, Inc. Developing autologous TIL cell therapies using a patient's own immune cells to fight solid tumors.	United States of America	TIL